E. Denizet, Pousse-seringues : attention aux seringues !, Annales Françaises d'Anesthésie et de Réanimation, vol.8, issue.3, p.295, 1989.

, Les résultats en matière de santé sont bons mais les dépenses sont élevées, 2017.

C. Meyniel and S. Wiertlewski, Névrites optiques, La Revue de Médecine Interne, vol.31, issue.7, pp.481-485, 2010.

J. Charcot, Deux cas de sclérose latérale symétrique amyotrophique, Leçons sur les Maladies du Système Nerveux, pp.402-424

T. Moreau, Coping et sclérose en plaques, Neuropsychologie de la sclérose en plaques, pp.47-54, 2010.

R. Milo and E. Kahana, Multiple sclerosis: Geoepidemiology, genetics and the environment, Autoimmunity Reviews, vol.9, issue.5, pp.A387-A394, 2010.

J. F. Kurtzke, A REASSESSMENT OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS, Acta Neurologica Scandinavica, vol.51, issue.2, pp.110-136, 2009.

A. Fromont, M. Lehanneur, F. Rollot, A. Weill, L. Clerc et al., Coûts de la sclérose en plaques en France, Revue Neurologique, vol.170, issue.6-7, pp.432-439, 2014.

D. Sadovnick, The place of environmental factors in multiple sclerosis: Genes, environment and the interactions thereof in the etiology of multiple sclerosis, Revue Neurologique, vol.175, issue.10, pp.593-596, 2019.

D. Brassat, Physiopathologie de la sclérose en plaques, La Presse Médicale, vol.39, issue.3, pp.341-348, 2010.

A. Compston and A. Coles, Multiple sclerosis, The Lancet, vol.372, issue.9648, pp.1502-1517, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00996686

P. Gourraud, H. F. Harbo, S. L. Hauser, and S. E. Baranzini, The genetics of multiple sclerosis: an up-to-date review, Immunological Reviews, vol.248, issue.1, pp.87-103, 2012.

N. Goncalves-mendes, J. Talvas, C. Dualé, A. Guttmann, G. Marceau et al., Impact d?une supplémentation en vitamine D sur les fonctions immunitaires et la réponse vaccinale chez des sujets âgés carencés, Nutrition Clinique et Métabolisme, vol.31, issue.3, pp.235-236, 2017.

S. Allal, Z. B. Bedrane, S. Benabadji, A. Merad, A. Reguig et al., Sclérose en plaques et Vitamine D?Étude prospective d?une cohorte de patients au CHU de Tlemcen, Revue Neurologique, vol.173, p.S126, 2017.

C. H. Hawkes, Smoking is a risk factor for multiple sclerosis: a metanalysis, Multiple Sclerosis Journal, vol.13, issue.5, pp.610-615, 2007.

J. Bach, The Effect of Infections on Susceptibility to Autoimmune and Allergic Diseases, New England Journal of Medicine, vol.347, issue.12, pp.911-920, 2002.

. Cayrol-r, Régulation Moléculaire De La Barrière Hémo-Encéphalique, Canada, 2014.

D. Laplaud, Mise au point sur la physiopathologie de la sclérose en plaques, Annals of Physical and Rehabilitation Medicine, vol.54, p.e290, 2011.

H. Babbe, A. Roers, A. Waisman, H. Lassmann, N. Goebels et al., Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction, Journal of Experimental Medicine, vol.192, issue.3, pp.393-404, 2000.

M. A. Rajhi, La sclérose en plaques : physiopathologie, thérapeutiques actuelles et futures

A. Rico, J. Pelletier, and B. Audoin, La sclérose en plaques, 2019.

D. Seilhean and D. Merkler, Anatomie pathologique de la sclérose en plaques et des maladies apparentées, La Sclérose en Plaques - Historique, épidémiologie et Pathogénie, pp.139-150, 2019.

L. Magy, La sclérose en plaques, Actualités Pharmaceutiques Hospitalières, vol.5, issue.19, pp.14-19, 2009.

A. Bertrand, S. Epelbeaum, and C. Denier, Sclérose en Plaque

L. David, C. Boinet, and T. , Sclérose en plaques du jeune adulte, Actual Pharm. févr, vol.59, issue.593, pp.15-24, 2020.

C. Papeix, C. Lubetzki, and O. Lyon-caen, Traitements actuels de la sclérose en plaques, La Presse Médicale, vol.39, issue.3, pp.381-388, 2010.

V. Durand, D. , L. Jeunne, and C. , Dorosz -Médicaments de la SEP (I) : Interférons bêta. 37 ème. Maloine, 2018.

É. Petit, Évolution et nouvelles perspectives dans la prise en charge thérapeutique de la sclérose en plaques, vol.138, 2015.

O. Gout, C. Bensa, and R. Assouad, Actualités thérapeutiques de la sclérose en plaques, La Revue de Médecine Interne, vol.31, issue.8, pp.575-580, 2010.

V. Durand, D. , L. Jeunne, and C. , Dorosz -Médicaments de la SEP (IV) : Immunomodulateur polypeptidique. 37 ème. Maloine, 1336.

R. Depaz, J. Aboab, and O. Gout, Actualités dans le diagnostic et la prise en charge thérapeutique de la sclérose en plaques, La Revue de Médecine Interne, vol.34, issue.10, pp.628-635, 2013.

C. M. Watson, A. N. Davison, D. Baker, J. K. O'neill, and J. L. Turk, Suppression of demyelination by mitoxantrone, International Journal of Immunopharmacology, vol.13, issue.7, pp.923-930, 1991.

V. Durand, D. , L. Jeunne, C. Dorosz--médicaments-de, and L. Sep,

(. Natalizumab and . Tysabri®, Guide des anticorps monoclonaux à usage thérapeutique -Juilllet, 2020.

D. Sur, Eau disponible pour l'utilisation, 2017.

M. Pérennes, C. Ollivier, and P. Lorillon, Place d?un nouvel anticorps monoclonal (natalizumab) dans la stratégie thérapeutique actuelle de la sclérose en plaques, Actualités Pharmaceutiques Hospitalières, vol.4, issue.13, pp.17-22, 2008.

V. Durand, D. , L. Jeunne, C. Dorosz--médicaments-de, and L. Sep, Immunosuppresseur (1). 37 ème. Maloine, 2018.

R. Hoepner, S. Faissner, A. Salmen, R. Gold, and A. Chan, Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis, Journal of Central Nervous System Disease, vol.6, p.JCNSD.S14049, 2014.

K. Bigaut, T. Fabacher, O. Outteryck, Z. Hélène, J. Ongagna et al., Efficacité à 10 ans du natalizumab dans une cohorte Française de patients avec une sclérose en plaques récurrente-rémittente : cohorte TYSTEN, Revue Neurologique, vol.175, p.S84, 2019.

C. Jacquet, S. Verclytte, M. Toledano, P. Hautecoeur, G. Calais et al., LEMP ou EMP chez une patiente porteuse d?une sclérose en plaques traitée par natalizumab ?, Revue Neurologique, vol.169, p.A107, 2013.

C. Lebrun and J. De-seze, Deux nouveaux traitements par voie orale dans la sclérose en plaques rémittente, Revue Neurologique, vol.170, issue.12, pp.721-722, 2014.

V. Durand, D. , L. Jeunne, and C. , Dorosz -Médicaments de la SEP (VII) et (VIII). 37ème. Maloine, p.p, 2018.

C. Lubetzki, Traitement de la sclérose en plaques : progrès et nouveaux défis, médecine/sciences, vol.29, issue.12, pp.1067-1068, 2013.

D. Pelletier and D. A. Hafler, Fingolimod for Multiple Sclerosis, New England Journal of Medicine, vol.366, issue.4, pp.339-347, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00617750

E. Havrdova, J. Cohen, D. Horáková, I. Kovarova, and E. Meluzinova, Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program, Therapeutics and Clinical Risk Management, vol.Volume 13, pp.1423-1437, 2017.

X. Montalban, S. L. Hauser, L. Kappos, D. L. Arnold, A. Bar-or et al., Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, New England Journal of Medicine, vol.376, issue.3, pp.209-220, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01793440

X. Montalban, S. L. Hauser, L. Kappos, D. L. Arnold, A. Bar-or et al., Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, New England Journal of Medicine, vol.376, issue.3, pp.209-220, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01793440

D. Sur,

M. Auer, G. Bsteh, H. Hegen, S. Wurth, A. Zinganell et al., Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab, Multiple Sclerosis and Related Disorders, vol.43, p.102155, 2020.

I. Adamec, ?. Reiner, I. Pe?in, N. ?u?ur, A. Godan-hauptman et al., Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis, Multiple Sclerosis and Related Disorders, vol.45, p.102381, 2020.

B. Stankoff, Neuroprotection et sclérose en plaques : bases et évaluation, p.1

P. Jeannin, S. Jaillon, and Y. Delneste, Biologie des récepteurs de l?immunité innée : applications cliniques et thérapeutiques, Revue Francophone des Laboratoires, vol.2010, issue.424, pp.41-51, 2010.

A. Leroyer and F. Dignat-georges, Cours d'immunologie « L'immunité innée et l'immunité adaptative »-L2 Pharmacie, 2015.

J. Joffre, R. Pirracchio, and M. Legrand, Réponse de l'endothélium microvasculaire à l'inflammation aiguë, Anesth Réanimation. sept, vol.6, issue.5, pp.493-502, 2020.

J. Joffre, J. Hellman, C. Ince, and H. Ait-oufella, Endothelial Responses in Sepsis, Am J Respir Crit Care Med. 1 août, vol.202, issue.3, pp.361-70, 2020.

H. Kolá?ová, B. Ambr?zová, ?. ?indlerová, L. Klinke, A. Kubala et al., Modulation of Endothelial Glycocalyx Structure under Inflammatory Conditions, Mediators Inflamm, 2014.

B. Opitz, S. Hippenstiel, J. Eitel, and N. Suttorp, Extra-and intracellular innate immune recognition in endothelial cells, Thromb Haemost, vol.98, issue.08, pp.319-345, 2007.

S. Danese, E. Dejana, and C. Fiocchi, Immune Regulation by Microvascular Endothelial Cells: Directing Innate and Adaptive Immunity, Coagulation, and Inflammation, J Immunol. 15 mai, vol.178, issue.10, pp.6017-6039, 2007.

A. Zarbock and K. Ley, Neutrophil Adhesion and Activation under Flow. Microcirculation, vol.16, issue.1, pp.31-42, 2009.

R. J. Melder, L. L. Munn, S. Yamada, C. Ohkubo, and R. K. Jain, Selectin-and integrin-mediated Tlymphocyte rolling and arrest on TNF-alpha-activated endothelium: augmentation by erythrocytes, Biophys J. nov, vol.69, issue.5, pp.2131-2139, 1995.

J. Al-omaishi, R. Bashir, and H. E. Gendelman, The cellular immunology of multiple sclerosis, J Leukoc Biol, vol.65, issue.4, pp.444-52, 1999.

N. J. Abbott, A. Patabendige, D. Dolman, S. R. Yusof, and D. J. Begley, Structure and function of the blood-brain barrier, Neurobiol Dis. janv, vol.37, issue.1, pp.13-25, 2010.

A. M. Butt, H. C. Jones, and N. J. Abbott, Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study, J Physiol. oct, vol.429, pp.47-62, 1990.

N. J. Abbott, L. Rönnbäck, and E. Hansson, Astrocyte-endothelial interactions at the blood-brain barrier, Nat Rev Neurosci. janv, vol.7, issue.1, pp.41-53, 2006.

T. G. Bush, N. Puvanachandra, C. H. Horner, A. Polito, T. Ostenfeld et al., Leukocyte Infiltration, Neuronal Degeneration, and Neurite Outgrowth after Ablation of Scar-Forming, Reactive Astrocytes in Adult Transgenic Mice, Neuron. juin, vol.23, issue.2, pp.297-308, 1999.

A. Armulik, G. Genové, M. Mäe, M. H. Nisancioglu, E. Wallgard et al., Pericytes regulate the blood-brain barrier, Nature, vol.468, issue.7323, pp.557-61, 2010.

A. Reboldi, C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli et al., C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE, Nat Immunol. mai, vol.10, issue.5, pp.514-537, 2009.

K. Ley, C. Laudanna, M. I. Cybulsky, and S. Nourshargh, Getting to the site of inflammation: the leukocyte adhesion cascade updated, Nat Rev Immunol. sept, vol.7, issue.9, pp.678-89, 2007.

L. Steinman, A molecular trio in relapse and remission in multiple sclerosis, Nat Rev Immunol. juin, vol.9, issue.6, pp.440-447, 2009.

D. W. Holman, R. S. Klein, and R. M. Ransohoff, The blood-brain barrier, chemokines and multiple sclerosis, Biochim Biophys Acta BBA -Mol Basis Dis. 1 févr, vol.1812, issue.2, pp.220-250, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00652656

K. Wosik, R. Cayrol, A. Dodelet-devillers, F. Berthelet, M. Bernard et al., Angiotensin II Controls Occludin Function and Is Required for Blood-Brain Barrier Maintenance: Relevance to Multiple Sclerosis, J Neurosci. 22 août, vol.27, issue.34, pp.9032-9074, 2007.

S. Leech, J. Kirk, J. Plumb, and S. Mcquaid, Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis, Neuropathol Appl Neurobiol, vol.33, issue.1, pp.86-98, 2007.

, Sabatier. Les Anticorps Monoclonaux Thérapeutiques -M1 UE 4 Faculté de Pharmacie, 2017.

M. Barczyk, S. Carracedo, and G. D. Integrins, Cell Tissue Res. 20 août, vol.339, issue.1, p.269, 2009.

D. A. Calderwood, S. J. Shattil, and M. H. Ginsberg, Integrins and Actin Filaments: Reciprocal Regulation of Cell Adhesion and Signaling, J Biol Chem. 28 juill, vol.275, issue.30, pp.22607-22617, 2000.

G. X. Yang and W. K. Hagmann, VLA-4 antagonists: Potent inhibitors of lymphocyte migration, Medicinal Research Reviews, vol.23, issue.3, pp.369-392, 2003.

B. Luo and T. A. Springer, Integrin structures and conformational signaling, Current Opinion in Cell Biology, vol.18, issue.5, pp.579-586, 2006.

Y. Hyun, C. T. Lefort, and M. Kim, Leukocyte integrins and their ligand interactions, Immunologic Research, vol.45, issue.2-3, pp.195-208, 2009.

D. Sur,

R. Gonzalez-amaro, M. Mittelbrunn, and F. Sanchez-madrid, Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords?, Immunology, vol.116, issue.3, pp.289-296, 2005.

R. O. Hynes, Integrins, Cell, vol.110, issue.6, pp.673-687, 2002.

R. A. Carter and I. P. Wicks, Vascular cell adhesion molecule 1 (CD106): A multifaceted regulator of joint inflammation, Arthritis & Rheumatism, vol.44, issue.5, pp.985-994, 2001.

M. Iademarco, Regulation of VCAM-1 Gene Expression in Inflammation

D. Sur, Eau disponible pour l'utilisation, 2017.

L. Poulouin, O. Gallet, and J. M. Imhoff, La fibronectine : propriétés et fonctions de la molécule native et de ses fragments, médecine/sciences, vol.13, issue.5, p.657, 1997.

J. Xu and D. Mosher, Fibronectin and Other Adhesive Glycoproteins, The Extracellular Matrix: an Overview, pp.41-75, 2010.

H. Berlin, Biology of Extracellular Matrix). Disponible sur, pp.41-75, 2011.

K. Ebnet, Junctional adhesion molecules (JAMs): more molecules with dual functions?, Journal of Cell Science, vol.117, issue.1, pp.19-29, 2004.

D. Kummer and K. Ebnet, Junctional Adhesion Molecules (JAMs): The JAM-Integrin Connection, Cells, vol.7, issue.4, p.25, 2018.

T. Ando, P. Jordan, Y. Wang, M. Itoh, T. Joh et al., Madcam-1 Expression and Regulation in Murine Colonic Endothelial Cells in Vitro, Inflammatory Bowel Diseases, vol.11, issue.3, pp.258-264, 2005.

Y. Yu, T. Schürpf, and T. A. Springer, How Natalizumab Binds and Antagonizes ?4Integrins, Journal of Biological Chemistry, vol.288, issue.45, pp.32314-32325, 2013.

D. Mendis, I. Ginon, H. Louis, J. L. Mcgregor, and R. N. Poston, Cell biotinylation provides a sensitive and effective detection technique for cellular adhesion assays: comparison with existing methods, Journal of Immunological Methods, vol.253, issue.1-2, pp.57-68, 2001.

A. Pierres, A. Benoliel, and P. Bongrand, Measuring the Lifetime of Bonds Made between Surface-linked Molecules, Journal of Biological Chemistry, vol.270, issue.44, pp.26586-26592, 1995.

A. Pierres, A. Benoliel, and P. Bongrand, Measuring the Lifetime of Bonds Made between Surface-linked Molecules, Journal of Biological Chemistry, vol.270, issue.44, pp.26586-26592, 1995.

O. Tissot, A. Pierres, C. Foa, M. Delaage, and P. Bongrand, Motion of cells sedimenting on a solid surface in a laminar shear flow, Biophysical Journal, vol.61, issue.1, pp.204-215, 1992.